FDA grants Roche’s pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
Media Release: Roche 02 08 2012Continue reading
FDA grants Roche’s pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer